Department of Radiology, Healts Sciences University, Bakirköy Dr. Sadi Konuk Training and Resarch Hospital, İstanbul-Turkey.
Department of General Surgery, Healts Sciences University, Bakirköy Dr. Sadi Konuk Training and Resarch Hospital, İstanbul-Turkey.
Ulus Travma Acil Cerrahi Derg. 2021 May;27(3):296-302. doi: 10.14744/tjtes.2020.23255.
The purpose of the study was to review the efficacy, safety, and outcomes of percutaneous cholecystostomy (PC) in elderly patients with acute calculous cholecystitis (ACC), high comorbidity, and COVID-19.
The hospital registry data were examined of patients aged >65 years who were diagnosed with ACC and COVID-19 between March 2020 and June 2020 and who underwent PC treatment in the interventional radiology unit.
A total of 18 patients were diagnosed with ACC and COVID-19, then underwent PC. The patients comprised 14 (78%) males and 4 (22%) females with an average age of 73.4 years (range, 67-81 years). In 17 (94%) patients, symptoms associated with acute cholecystitis decreased within 48-72 h of the PC treatment and a clinical improvement was determined. The success rate of PC was 100% and no complications. In 3 (16.6%) patients followed up with intubation in intensive care after the procedure, mortality developed due to COVID-19-associated pneumonia and subsequent acute respiratory distress syndrome, and 15 (83.4%) patients were discharged with an elective cholecystectomy plan.
COVID-19 infection can be fatal especially in patients over 65 years of age due to additional comorbidities. PC treatment, which can be performed under local anesthesia as a minimally invasive procedure, is an alternative treatment option in this patient group. PC can also act as a bridge in transition to elective surgery in this process management.
本研究旨在回顾经皮胆囊造口术(PC)在患有急性结石性胆囊炎(ACC)、合并症高和 COVID-19 的老年患者中的疗效、安全性和结果。
对 2020 年 3 月至 2020 年 6 月期间在介入放射科因 ACC 和 COVID-19 接受 PC 治疗的 >65 岁患者的医院登记数据进行了检查。
共有 18 例被诊断为 ACC 和 COVID-19 的患者接受了 PC 治疗。这些患者包括 14 名(78%)男性和 4 名(22%)女性,平均年龄为 73.4 岁(范围为 67-81 岁)。在 17 名(94%)患者中,急性胆囊炎相关症状在 PC 治疗后 48-72 小时内减轻,并确定了临床改善。PC 的成功率为 100%,无并发症。在 3 名(16.6%)患者中,在程序后在重症监护室进行插管,由于 COVID-19 相关肺炎和随后的急性呼吸窘迫综合征而导致死亡,15 名(83.4%)患者出院并计划择期行胆囊切除术。
COVID-19 感染尤其在 65 岁以上的患者中可能是致命的,因为存在额外的合并症。PC 治疗作为一种微创程序,可以在局部麻醉下进行,是该患者群体的另一种治疗选择。在这一过程管理中,PC 也可以作为过渡到择期手术的桥梁。